Drug Trial Radar · NCT07823608
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
258
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Apr 30, 2028
Study completion Jun 18, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who use a breathing machine (positive airway pressure \[PAP\] machine). People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training. During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.
Conditions
- Apnea
- Sleep Disorders
- Overweight and/or Obesity
Interventions
BerobenatideDrug
By Subcutaneous Injection
PlaceboOther
By Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Apnea-Hypopnea Index (AHI)Time frame: baseline, Week 52
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Cullman Clinical Trials
Cullman, Alabama · Recruiting
Preferred Research Partners, Inc.
Little Rock, Arkansas · Recruiting
Probe Clinical Research Corporation
Riverside, California · Recruiting
DM Clinical Research
Bradenton, Florida · Recruiting
Revive Research Institute, Inc.
Southfield, Michigan · Not yet recruiting
Headlands Research - Twin Cities
Maplewood, Minnesota · Recruiting
Velocity Clinical Research, Dallas
Dallas, Texas · Recruiting
DM Clinical Research
Tomball, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.